Comparison of Efficacy of Pharmacologic Treatments in Pregnancy- and Lactation-Associated Osteoporosis

  • Namki Hong
  • Yumie RheeEmail author


Pregnancy- and lactation-associated osteoporosis (PLO) is a rare disorder characterised by the occurrence of multiple fragility fractures, particularly at vertebral columns, in the third trimester or early postpartum period. Whether implementation for pharmacologic treatments in patients with PLO remains controversial partly due to rarity of data and known indolent recovery of bone mass after fracture, various pharmacologic treatments have been reported to effectively facilitate bone mineral density (BMD) increase in anecdotal case reports or cohorts based on individualised clinical assessment of subsequent fracture risk. In this study, we aimed to summarise pharmacologic strategies and its efficacy on BMD change and subsequent fractures using individual case data or frequency-weighted group data from available literatures. Among 2438 studies identified using PubMed and Embase until Jan 2019, 30 studies which reported pharmacologic treatment (23 studies) or observation (7 studies) were included. Reported treatment options consisted of observation with calcium/vitamin D supplements (control, n = 32), bisphosphonates (BP, n = 31), teriparatide (TPTD, n = 40) and other strategies (vitamin K2 and strontium; other, n = 4). Median treatment duration and BMD follow-up duration was 27 and 35 months, respectively. Mean lumbar spine BMD measured by dual-energy x-ray absorptiometry was increased at 3-year follow-up in all groups (control, 7.9%; BP, 18.2%; TPTD, 17.0%; other, 8.6%; P < 0.05 for all), with significantly higher BMD change in BP or TPTD compared to control (Bonferroni-corrected P < 0.001 for all). Our findings suggest the potential long-term efficacy of pharmacologic treatments in individuals with PLO with high risk of subsequent fracture.


Pregnancy- and lactation-associated osteoporosis Premenopausal women Vertebral fracture Bisphosphonates Recombinant human parathyroid hormone (1–34) 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

Not applicable.

Informed Consent

Not applicable.


  1. 1.
    Nordin BE, Roper A. Post-pregnancy osteoporosis; a syndrome? Lancet. 1955;268(6861):431–4.CrossRefGoogle Scholar
  2. 2.
    Dunne F, Walters B, Marshall T, Heath DA. Pregnancy associated osteoporosis. Clin Endocrinol. 1993;39(4):487–90.CrossRefGoogle Scholar
  3. 3.
    Phillips AJ, Ostlere SJ, Smith R. Pregnancy-associated osteoporosis: does the skeleton recover? Osteoporos Int. 2000;11(5):449–54. Scholar
  4. 4.
    Hong N, Kim JE, Lee SJ, Kim SH, Rhee Y. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol. 2018;88(5):652–8. Scholar
  5. 5.
    Kyvernitakis I, Reuter TC, Hellmeyer L, Hars O, Hadji P. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int. 2018;29(1):135–42. Scholar
  6. 6.
    Li LJ, Zhang J, Gao P, Lv F, Song YW, Chang XY, et al. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis. Clin Rheumatol. 2018;37(11):3141–50. Scholar
  7. 7.
    Laroche M, Talibart M, Cormier C, Roux C, Guggenbuhl P, Degboe Y. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int. 2017;28(11):3135–42. Scholar
  8. 8.
    Hadji P, Boekhoff J, Hahn M, Hellmeyer L, Hars O, Kyvernitakis I. Pregnancy-associated osteoporosis: a case-control study. Osteoporos Int. 2017;28(4):1393–9. Scholar
  9. 9.
    O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006;17(7):1008–12. Scholar
  10. 10.
    Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, Papaioannou NA. Case report: teriparatide treatment in a case of severe pregnancy- and lactation-associated osteoporosis. Hormones (Athens, Greece). 2012;11(4):495–500.CrossRefGoogle Scholar
  11. 11.
    Stumpf UC, Kurth AA, Windolf J, Fassbender WJ. Pregnancy-associated osteoporosis: an underestimated and underdiagnosed severe disease. A review of two cases in short- and long-term follow-up. Adv Med Sci. 2007;52:94–7.Google Scholar
  12. 12.
    Jang JY, Lee JG, Jeong IK, Ahn KJ, Chung HY, Yang HI, et al. A case of post-pregnancy osteoporosis combined with ankylosing spondylitis. Rheumatol Int. 2009;29(11):1359–62. Scholar
  13. 13.
    Allali F, Guedirra N, Hajjaj-Hassouni N. A case of post-pregnancy osteoporosis-related spinal fractures in association with ankylosing spondylitis. Clin Rheumatol. 2005;24(4):435–6. Scholar
  14. 14.
    Tran HA, Petrovsky N. Pregnancy-associated osteoporosis with hypercalcaemia. Intern Med J. 2002;32(9–10):481–5.CrossRefGoogle Scholar
  15. 15.
    Rillo OL, Di Stefano CA, Bermudez J, Maldonado Cocco JA. Idiopathic osteoporosis during pregnancy. Clin Rheumatol. 1994;13(2):299–304.CrossRefGoogle Scholar
  16. 16.
    Grizzo FM, da Silva Martins J, Pinheiro MM, Jorgetti V, Carvalho MD, Pelloso SM. Pregnancy and lactation-associated osteoporosis: bone histomorphometric analysis and response to treatment with zoledronic acid. Calcif Tissue Int. 2015;97(4):421–5. Scholar
  17. 17.
    Tanriover MD, Oz SG, Sozen T, Kilicarslan A, Guven GS. Pregnancy- and lactation-associated osteoporosis with severe vertebral deformities: can strontium ranelate be a new alternative for the treatment? Spine J. 2009;9(4):e20–4. Scholar
  18. 18.
    Smith R, Athanasou NA, Ostlere SJ, Vipond SE. Pregnancy-associated osteoporosis. QJM. 1995;88(12):865–78.Google Scholar
  19. 19.
    Blanch J, Pacifici R, Chines A. Pregnancy-associated osteoporosis: report of two cases with long-term bone density follow-up. Br J Rheumatol. 1994;33(3):269–72.CrossRefGoogle Scholar
  20. 20.
    Zhang M, Chen P, Li B, Du J, Pan T, Chen J. Approach to the patient with pregnancy and lactation-associated osteoporosis: a case report and a review of the literature. Medicine (Baltimore). 2017;96(46):e8671. Scholar
  21. 21.
    Honjo S, Mizunuma H. Changes in biochemical parameters of bone turnover and bone mineral density in post-pregnancy osteoporosis. Am J Obstet Gynecol. 2001;185(1):246–7. Scholar
  22. 22.
    Anai T, Tomiyasu T, Arima K, Miyakawa I. Pregnancy-associated osteoporosis with elevated levels of circulating parathyroid hormone-related protein: a report of two cases. J Obstet Gynaecol Res. 1999;25(1):63–7.CrossRefGoogle Scholar
  23. 23.
    Sarikaya S, Ozdolap S, Acikgoz G, Erdem CZ. Pregnancy-associated osteoporosis with vertebral fractures and scoliosis. Joint Bone Spine. 2004;71(1):84–5. Scholar
  24. 24.
    Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int. 2012;32(3):819–23. Scholar
  25. 25.
    Reid IR, Wattie DJ, Evans MC, Budayr AA. Post-pregnancy osteoporosis associated with hypercalcaemia. Clin Endocrinol. 1992;37(3):298–303.CrossRefGoogle Scholar
  26. 26.
    Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I, et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol. 2008;35(12):2344–7. Scholar
  27. 27.
    Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(6):3209–14. Scholar
  28. 28.
    Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol. 1993;121(2):217–23. Scholar
  29. 29.
    Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428–30. Scholar
  30. 30.
    Cohen A. Premenopausal osteoporosis. Endocrinol Metab Clin N Am. 2017;46(1):117–33. Scholar
  31. 31.
    Cohen A, Stein EM, Recker RR, Lappe JM, Dempster DW, Zhou H, et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab. 2013;98(5):1971–81. Scholar
  32. 32.
    Fazeli PK, Wang IS, Miller KK, Herzog DB, Misra M, Lee H, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab. 2014;99(4):1322–9. Scholar
  33. 33.
    Choe EY, Song JE, Park KH, Seok H, Lee EJ, Lim SK, et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab. 2012;30(5):596–601. Scholar
  34. 34.
    Polat SB, Evranos B, Aydin C, Cuhaci N, Ersoy R, Cakir B. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol. 2015;31(7):522–5. Scholar
  35. 35.
    Coskun Benlidayi I, Sarpel T, Guzel R. Short-term treatment experience with teriparatide in pregnancy- and lactation-associated osteoporosis. J Obstet Gynaecol. 2014;34(8):736. Scholar
  36. 36.
    Hellmeyer L, Boekhoff J, Hadji P. Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Gynecol Endocrinol. 2010;26(10):725–8. Scholar
  37. 37.
    Ijuin A, Yoshikata H, Asano R, Tsuburai T, Kikuchi R, Sakakibara H. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: a case study. Taiwan J Obstet Gynecol. 2017;56(6):863–6. Scholar
  38. 38.
    Cohen A, Kamanda-Kosseh M, Recker RR, Lappe JM, Dempster DW, Zhou H, et al. Bone density after teriparatide discontinuation in premenopausal idiopathic osteoporosis. J Clin Endocrinol Metab. 2015;100(11):4208–14. Scholar
  39. 39.
    Tsuchie H, Miyakoshi N, Hongo M, Kasukawa Y, Ishikawa Y, Shimada Y. Amelioration of pregnancy-associated osteoporosis after treatment with vitamin K(2): a report of four patients. Ups J Med Sci. 2012;117(3):336–41. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Severance Hospital, Endocrine Research InstituteYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations